With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growthRevenue growthYear-over-year change in revenue, expressed as a percentage. The starting point for any forward-earnings model and the lens through which scale, mix, and pricing power become visible. and high operating margins (~37%), it generates strong and predictable free cash flowFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics..
A macroeconomic shock compressing discretionary pet spending combined with a cyclical livestock downturn would threaten historical 37% operating margins. The reverse DCFReverse DCFInverts a standard DCF: instead of solving for fair value, we solve for the growth rate the current price already implies — a useful test of whether the market's assumptions are reasonable. implies the market is already pricing in a structural decay (-2.52% perpetual growth), providing a massive margin of safetyMargin of safetyThe discount required between fair value and current price before we recommend buying. Typically 15% for wide-moat names, 25–35% for cyclicals or low-confidence cases. against such cyclical shocks.
Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.
Prolonged livestock disease cycle reduces the agricultural segment revenues structurally, dragging corporate growth.
Deep recession forces broad reduction in discretionary companion animal treatments and veterinary visits.
| Line item | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Revenue | $8.08B | $8.54B+5.7% | $9.26B+8.4% | $9.47B+2.3% | +5.4% |
| Gross profit | $5.63B | $5.98B | $6.54B | $6.80B | +6.5% |
| Operating income | $2.93B | $3.07B | $3.39B | $3.60B | +7.1% |
| Net income | $2.11B | $2.34B+10.9% | $2.49B+6.4% | $2.67B+7.2% | +8.1% |
| EPS (diluted) | $4.49 | $5.07 | $5.47 | $6.02 | +10.3% |
| EBITDA | $3.34B | $3.67B | $3.86B | $4.07B | +6.8% |
| R&D | $539.0M | $614.0M | $686.0M | $698.0M | +9.0% |
| SG&A | $2.01B | $2.15B | $2.32B | $2.38B | +5.8% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Erosion of the 71.8% gross margin floor. | Monitor | Deterioration versus the report thesis |
| Accelerated generic approvals targeting core parasiticide or dermatology portfolios. | Monitor | Deterioration versus the report thesis |
